2013
DOI: 10.1007/s00706-013-1029-0
|View full text |Cite
|
Sign up to set email alerts
|

Edaravone cocrystals: synthesis, screening, and preliminary characterization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 50 publications
0
2
0
Order By: Relevance
“…The case study compound, PROPY, shows structural similarity to two other compounds, antipyrine and edaravone, which contain the same molecular skeleton (phenylpyrazole); however PROPY contains an isopropyl substituent which causes steric hindrance at the carbonyl (Figure ). A number of multicomponent systems have been reported for antipyrine and edaravone, from which additional knowledge can be gained and can be used in the design and search for cocrystals of PROPY. An analysis of these systems indicates that most of the coformers feature CO 2 H donor groups.…”
Section: Resultsmentioning
confidence: 99%
“…The case study compound, PROPY, shows structural similarity to two other compounds, antipyrine and edaravone, which contain the same molecular skeleton (phenylpyrazole); however PROPY contains an isopropyl substituent which causes steric hindrance at the carbonyl (Figure ). A number of multicomponent systems have been reported for antipyrine and edaravone, from which additional knowledge can be gained and can be used in the design and search for cocrystals of PROPY. An analysis of these systems indicates that most of the coformers feature CO 2 H donor groups.…”
Section: Resultsmentioning
confidence: 99%
“…It has been reported that it can eliminate lipid peroxides and hydroxyl radicals. Edaravone was developed by Mitsubishi Tanabe Pharma Corporation and was approved to improve neurological symptoms, activities of daily living, and dysfunction caused by acute cerebral infarction in Japan, in 2001. In 2017, the US Food and Drug Administration approved edaravone for the treatment of patients with amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease. Therefore, the demand for edaravone is increasing in the current market.…”
Section: Introductionmentioning
confidence: 99%